These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 28822777)

  • 41. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
    Stephens JW; Brown KE; Min T
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The potential for renoprotection with incretin-based drugs.
    Tanaka T; Higashijima Y; Wada T; Nangaku M
    Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy with SGLT2 inhibitors for diabetic kidney disease.
    Cai Y; Liu X; Xu G
    Biomed Pharmacother; 2020 Jul; 127():110192. PubMed ID: 32559844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention.
    McGrath K; Edi R
    Am Fam Physician; 2019 Jun; 99(12):751-759. PubMed ID: 31194487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.
    Fei Y; Tsoi MF; Kumana CR; Cheung TT; Cheung BMY
    Int J Cardiol; 2018 Mar; 254():291-296. PubMed ID: 29277321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
    Škrtić M; Cherney DZ
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
    Bae EJ
    Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of CVOTs in primary and secondary prevention of kidney disease.
    De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
    Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
    Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
    Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glucose lowering and the kidney: are all drug classes equal?
    Wong MG; Jardine M; Perkovic V
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
    [No Abstract]   [Full Text] [Related]  

  • 54. Not only incretins for diabetic kidney disease-beneficial effects by DPP-4 inhibitors.
    Nangaku M; Wanner C
    Kidney Int; 2021 Feb; 99(2):318-322. PubMed ID: 33509354
    [No Abstract]   [Full Text] [Related]  

  • 55. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.
    Steen O; Goldenberg RM
    Can J Diabetes; 2017 Oct; 41(5):517-523. PubMed ID: 28942789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of diabetic kidney disease: current and future targets.
    Kim MK
    Korean J Intern Med; 2017 Jul; 32(4):622-630. PubMed ID: 28704915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].
    Scheen AJ
    Rev Med Liege; 2015 Dec; 70(12):593-9. PubMed ID: 26867302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
    Game F
    Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.